Clinical question: Does transfusing platelets to preterm infants (< 34 weeks) at a higher platelet count threshold count (< 50 x 10 9 /L) reduce the risk of major bleeding or death compared to only transfusing platelets when the platelet count drops below 25 x 10 9 /L.
Platelet transfusions are commonly given to prevent bleeding in preterm infants with a low platelet count (Curley et al., 2018) . However, there has been a lack of evidence on the appropriate platelet count threshold from randomised controlled trials (RCTs) (New, et al., 2016; Sola-Visner & Bercovitz, 2016) . There has therefore been a wide variation in practice within and between countries (Stanworth et al., 2009; Cremer et al., 2011; Sparger et al., 2015) . This is the first RCT that has assessed different platelet count thresholds in neonates with very low platelet counts (< 50 x 10 9 /L). This Transfusion Evidence Synopsis summarises the paper describing this RCT in the NEJM (Curley et al., 2018) (Box 1).
Summary of the results of the study
The study achieved a well-defined contrast in treatment between the study arms; many more babies in the high-threshold group (90%) received a platelet transfusion (Table 1) 9 /L, cranial ultrasonography (< 6 h prior to randomisation), no major intraventricular haemorrhage. Exclusion criteria: major/life-threatening congenital malformation, major bleeding within 72 h, intracranial haemorrhage, immune thrombocytopenia, parenteral vitamin K not given, very poor life expectancy. Comparison: platelet transfusion (15 mL/kg) when platelet count <50 x 10 9 /L (high-threshold group) versus when platelet count <25 x 10 9 /L (low-threshold group). Primary outcome: death or major bleeding within 28 days. Secondary outcomes: death, major bleeding, moderate bleeding, minor bleeding, chronic lung disease, retinopathy of prematurity, discharge from hospital, number of platelet transfusions, proportion receiving platelet transfusions, sepsis, necrotising enterocolitis, serious adverse events, transfusion-related adverse events, neurodevelopmental outcome at 2 years (not yet reported).
The main finding was that giving platelet transfusions at the higher threshold to prevent bleeding increased the risk of death or major bleeding (Table 1) . This was a completely unexpected finding as the study's hypothesis was that it would decrease the risk of death or major bleeding. The reasons for this difference are unknown.
There was a significant increase in the number of babies who were diagnosed with bronchopulmonary dysplasia in the 1 The odds ratios and hazards ratios were adjusted for trial site, intrauterine growth restriction and gestational age at birth.
high threshold group. There was no evidence of a difference in the numbers who developed retinopathy of prematurity, sepsis, necrotising enterocolitis or any serious adverse event during the trial. There was borderline evidence of a decrease in the number of babies discharged from hospital by 38 weeks' corrected gestational age in the high-threshold group (Table 1) .
Limitations of the trial
A total of 3·2% (45 of 1393) of platelet transfusions were given when they were not indicated by the protocol, and more of these were given in the low-threshold group (87%; 39/45). There were also 124 episodes when the indications for giving a transfusion were met but no transfusion was given, and more of these instances occurred in the high-threshold group (76%; 94/124). However, when per-protocol analyses were performed, there was no significant difference in the findings, and the discrepancies in the trial protocol would not have introduced a systematic bias between the randomised groups as the protocol deviations tended to reduce the difference in the number of transfusions given to high-and to the low-threshold groups.x Only 37% of infants were recruited within 5 days of birth; therefore, these findings are more relevant to infants with late-onset thrombocytopenia due to sepsis or necrotising enterocolitis rather than thrombocytopenia that develops within the first 3 days of life.
Evidence in context
This is the first large RCT of prophylactic platelet transfusion in premature neonates with very low platelet counts. Previous observational studies have suggested harms associated with giving platelet transfusions (Curley et al., 2018) .
Implications for research
The unexpected findings of increased deaths and increases in bronchopulmonary dysplasia in the high-threshold group prompt further study. Taken together, these results pose several questions for future work to understand the pathology and improve the management of haemorrhage and bronchopulmonary dysplasia in premature neonates.
Implications for practice
This trial supports the advice given by BSH to use a threshold of 25 x 10 9 /L to guide administration of platelet transfusions in premature neonates who are not bleeding and do not require surgery (New, et al., 2016) . It clearly indicates that higher transfusion thresholds for prophylactic platelets in this age group are not indicated and may be harmful.
